Similar articles

• [Osteoporosis and bisphosphonates].

  Zuber MA. Zuber MA. Z Rheumatol. 2007 Dec;66(8):713-5. doi: 10.1007/s00393-007-0227-8. Z Rheumatol. 2007. PMID: 17955251 German. No abstract available.
• [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].

  Ringe JD. Ringe JD. MMW Fortschr Med. 2009 Mar 5;151(10):7. MMW Fortschr Med. 2009. PMID: 19472655 German. No abstract available.
• Alendronate and atrial fibrillation.

  Cummings SR, Schwartz AV, Black DM. Cummings SR, et al. N Engl J Med. 2007 May 3;356(18):1895-6. doi: 10.1056/NEJMc076132. N Engl J Med. 2007. PMID: 17476024 No abstract available.
• Bisphosphonates and the risk of atrial fibrillation.

  Sewerynek E, Stuss M. Sewerynek E, et al. Endokrynol Pol. 2011 Jan-Feb;62(1):93-6. Endokrynol Pol. 2011. PMID: 21365587 Review.
• Annual zoledronic acid for osteoporosis.

  BMJ Group. BMJ Group. Drug Ther Bull. 2008 Dec;46(12):93-6. Drug Ther Bull. 2008. PMID: 19056701 Review.